AbbVie and Galapagos extend GLPG0634 collaboration

Monday, June 10, 2013

Galapagos, which specialized in novel modes-of-action, and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn’s disease. Galapagos will fund and complete a phase II program in Crohn’s, designed to facilitate rapid progression into phase III.  Upon successful completion of the study, expected in the second quarter of 2015, AbbVie will pay Galapagos $50 million. 

[Read More]

Galapagos acquires Cangenix

Wednesday, January 16, 2013

Galapagos, a mid-size clinical stage biotechnology company, has acquired Cangenix, a gene-to-structure biotech company, to add structure-based drug discovery to its Argenta service offering. Cangenix’s state-of-the-art technology will augment Argenta’s ability to design new drugs and fill a growing client need.

[Read More]